Cancer treatment systems maker BSD Medical Corp (BSDM) has announced encouraging results from its distribution efforts for the MicroThermX Microwave Ablation products for soft tissue ablation (destruction).
The Utah-based company reported that increased promotional activity of its MicroThermX products, at the hospital level, by trained sale representatives has resulted in a full schedule of clinical evaluation by the physicians interested in using the device over the coming weeks. This accelerated clinical evaluation by hospitals represents a key milestone for BSD Medical, manifesting the early success in rolling out its distribution strategy for the product.
BSD Medical also noted that medical facilities, where it initially placed the MicroThermX systems, continue to reorder disposable microwave antennas, thereby validating the revenue opportunity that the company envisions. Moreover, the existing users of the device have reported positive clinical outcome in treating tumors.
BSD Medical is progressing well in its ongoing efforts to establish a dedicated specialty distribution network for the MicroThermX products. The company has strategized to use the network of specialty distribution firms, who market products in the interventional radiology area. Moreover, BSD Medical is expanding its marketing and sales force to support the roll-out of its MicroThermX products.
The innovative MicroThermX system was introduced in the U.S. in December 2010. Subsequently, BSD Medical successfully launched its first MicroThermX system in Europe in January 2011.
The MicroThermX system leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.
BSD Medical competes with established players like Boston Scientific (BSX) and Angiodynamics (ANGO) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
Be the first to comment